Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus.

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

Abbreviations: RECIST, Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;

Genetic susceptibility: Polymorphisms of the 8q24 chromosome S. Lani Park 05/07/09.

Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Novel Colon Cancer Tumor Suppressor Gene, Defensin-β1, Predicts Recurrence in Patients with Stage II and III Colon Cancer. Melissa J. LaBonte 1/2, Pierre.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.

*University Hospital Gasthuisberg, Leuven, Belgium

ICAM-1, GRP-78 and NFkB gene polymorphisms associated with clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU.

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Germline polymorphisms in the CD44 gene are associated with clinical outcome in localized gastric adenocarcinoma. Thomas Winder, M.D. University of Southern.

S. K. Anderson 1, J. M. Lafky 1, X. W. Carrero 1, T. K. Kimlinger 1, T. M. Halling 1, S. Kumar 1, P. J. Flynn 2, H. M. Gross 3, K. A. Jaeckle 4, J. C.

Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.

Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

Presented By Alan Venook at 2016 ASCO Annual Meeting

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

CCO Independent Conference Coverage

Correlation of tumor mutation burden and chemotherapy outcomes

colorectal cancer: The Multiethnic Cohort

Prognostic Implications of Neutrophil to Lymphocyte Ratio in the Treatment of Metastatic Renal Cell Carcinoma with Pazopanib and Sunitinib Ajay Raghunath1,

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

University of Southern California, Norris Comprehensive Cancer Center

TBCRC (the translational breast cancer research consortium) 005 Prospective study

VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun.

EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

BRAF mutant mCRC patients – What would you recommend? FOLFIRINOX/Bev

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

A subgroup analysis of a large multicenter study

Published online September 20, 2017 by JAMA Surgery

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal cancer (CRC) is generally characterized by aberrant Wnt signaling. The Wnt signaling pathway was found to be deregulated in 93% of colorectal cancer. Wnt signaling pathway genes AXIN2 and TCF7L2 complex control the proliferation and differentiation of intestinal epithelial cells. Our previous study showed polymorphisms in TCF7L2 and AXIN2 were associated with increase risk of colon cancer. Hence, we tested the hypothesis whether single nucleotide polymorphisms (SNPs) in TCF7L2 (rs ) and AXIN2 (rs , rs ) will predict clinical outcome in a cohort of mCRC pts treated with first line FOLFIRI/BEV. DNA was extracted from 424 patients’ blood or tissue treated with first-line FOLFIRI+BV and prospectively enrolled in a prospective pharmacogenomic translational study. Median follow up is 45.1 months and median PFS and OS were 10.4 and 27.3 months, respectively. Three functionally significant SNPs: TCF7L2 (rs ) and AXIN2 (rs , rs ) were analyzed by PCR-based direct sequencing. All candidate SNPs were analyzed for association with tumor response rate (RR), progression free survival (PFS), and overall survival (OS). The associations between genetic variants and clinical outcome were examined using χ 2 test, log-rank test, and Cox regression models whenever appropriate. All tests were 2-sided and p values were not adjusted for multiple testing. Table 1. Baseline characteristics of the 424 patients included in the biomarker analysis. Genetic variants in Wnt signaling pathway predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients(pts) treated with first-line FOLFIRI and Bevacizumab(FOLFIRI/BEV) Yan Ning 1, Wu Zhang 1, Dongyun Yang 1, Fotios Loupakis 2, Takeru Wakatsuki 1, Sebastian Stintzing 1, Nico B Volz 1, Rita E El-Khoueiry 1, Joseph E Li 1, Melissa LaBonte 1, Federica Marmorino 2, Chiara Cremolini 2, Afsaneh Barzi 1, Anthony El-Khoueiry 1, Heinz-Josef Lenz 1 1 USC/Norris Comprehensive Cancer Center, Los Angeles, CA; 2 U.O. Oncologia Medica 2 – Aziendo Ospedaliero-Universitaria Pisana, Pisa, Italy Patient Characteristics Abstract ID: 3568 Results Our data show for the first time Wnt signaling pathway gene polymorphisms TCF7L2 rs and AXIN2 rs may predict PFS and OS in mCRC pts treated with first-line FOLFIRI/BEV. More importantly, this predictive value is dependent on gender and tumor location, suggesting a different role of Wnt signaling in female vs male and in right vs left side tumor. Our preliminary data warrants clinical trial validation. Figure 1. In male, pts with any T allele of TCF7L2 rs had worse OS (p=0.029) and PFS (p=0.014) in right-sided tumors compared to those carrying C/C genotype (P for interaction = 0.047) (OS). Table 2. Significant TCF7L2 rs and AXIN rs polymorphisms and clinical outcome in first-line FOLFIRI+BV therapy. Figure 2. In female, TCF7L2 rs concluded pts with any T (CT/TT) allele were significantly associated with better OS and PFS compared to those with CC genotypes by tumor location. Pts with C/C genotype in left-side tumor had worse OS (p=0.037); Pts with C/C genotype in right-side tumor had worse PFS (p=0.022). Figure 3. Tumor response of TCF7L2 rs and AXIN rs in male pts.